Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bright Minds Biosciences Inc DRUG


Primary Symbol: C.DRUG

Healthcare Biotechnology
Bright Minds Biosciences Inc. is a biotechnology company. The Company is focused on developing transformative treatments for neuropsychiatric disorders, epilepsy, and pain. It has a portfolio of next generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as treatment resistant epilepsy, treatment resistant... see more

Recent & Breaking News (CSE:DRUG)

Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties

GlobeNewswire May 2, 2022

Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders

GlobeNewswire April 19, 2022

Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial

GlobeNewswire March 14, 2022

Bright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare Conference

GlobeNewswire March 8, 2022

Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference

GlobeNewswire January 4, 2022

Canadian Securities Exchange's November 2021 Performance Includes Strong Listings Growth and New Financing Milestone

Newsfile December 15, 2021

Bright Minds Biosciences to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference

GlobeNewswire December 6, 2021

Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases

GlobeNewswire November 30, 2021

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol "DRUG"

GlobeNewswire November 3, 2021

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

PR Newswire October 18, 2021

Bright Minds Biosciences Inc. to Webcast Live At VirtualInvestorConferences.com October 14th

PR Newswire October 7, 2021

Bright Minds Biosciences to Present at the LD Micro Main Event Small Cap Investment Conference

GlobeNewswire October 6, 2021

Bright Minds Biosciences Provides Scientific Update

GlobeNewswire September 22, 2021

Bright Minds Biosciences to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference; Shares Now Eligible for DTC Clearance

GlobeNewswire September 8, 2021

Bright Minds Biosciences ("BMB") Proprietary 5-HT2C Agonist Shows Significant Reduction in Seizure Activity

GlobeNewswire August 18, 2021

Bright Minds Biosciences Announces Application to List on Nasdaq

GlobeNewswire June 16, 2021

Bright Minds Biosciences Appoints New Board Member and Expands Leadership Team

GlobeNewswire June 14, 2021

Bright Minds Biosciences to Present at the H.C. Wainwright Virtual Conference Psychedelics in Psychiatry and Beyond

GlobeNewswire June 11, 2021

Bright Minds Biosciences to Present at the 2021 LD Micro Invitational XI

GlobeNewswire June 9, 2021

Bright Minds Biosciences Shares to Commence Trading on the OTCQB Venture Market on May 17, 2021

GlobeNewswire May 17, 2021